Honigman Advises CB Biotechnology on Up to $254 Million Pending Acquisition of Theratechnologies

Honigman advised CB Biotechnology - an affiliate of Future Pak, a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products - on signing its take private acquisition of Theratechnologies (Nasdaq: THTX), a specialty biopharmaceutical company focused on the commercialization of innovative therapies. The deal is worth up to $254 million.

The transaction is expected to close on or about November 30, 2025, subject to customary closing conditions.

Honigman advised CB Biotechnology in the acquisition. The team was led by Corporate Partners Nicholas Pedersen and Jeffrey H. Kuras, with support from Associate Gareth T. Ulmer. Financing counsel was provided by Partners Kimberly A. Dudek and David J. Axelson, with support from Associate Sarah A. Schade-McCarter.

Read more about the acquisition here.